Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol in Acute Myocardial Infarction
NCT06376630Recruiting
- Start
- Jan 2024
- Primary completion
- Jan 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of esmolol in myocardial infarction (MI) (3 arms). Primary endpoint: Composite of adverse cardiac outcomes at 12 months. Started Jan 2024; status: recruiting.
02
Drugs
esmolol
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT06376630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06376630.